WO2001021207A3 - Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines - Google Patents

Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines Download PDF

Info

Publication number
WO2001021207A3
WO2001021207A3 PCT/EP2000/009366 EP0009366W WO0121207A3 WO 2001021207 A3 WO2001021207 A3 WO 2001021207A3 EP 0009366 W EP0009366 W EP 0009366W WO 0121207 A3 WO0121207 A3 WO 0121207A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccines
octoxynol
combination
polyoxyethylene sorbitan
sorbitan ester
Prior art date
Application number
PCT/EP2000/009366
Other languages
French (fr)
Other versions
WO2001021207A2 (en
Inventor
Martin Friede
Philippe Hermand
Veronique Henerickx
Original Assignee
Smithkline Beecham Biolog
Martin Friede
Philippe Hermand
Veronique Henerickx
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9922703.5A external-priority patent/GB9922703D0/en
Priority claimed from GB0016685A external-priority patent/GB0016685D0/en
Priority to KR1020027003832A priority Critical patent/KR20020038770A/en
Priority to HU0202885A priority patent/HUP0202885A3/en
Priority to EP00969296A priority patent/EP1221971A2/en
Priority to MXPA02003067A priority patent/MXPA02003067A/en
Priority to JP2001524631A priority patent/JP2003509473A/en
Priority to AU79070/00A priority patent/AU765824B2/en
Application filed by Smithkline Beecham Biolog, Martin Friede, Philippe Hermand, Veronique Henerickx filed Critical Smithkline Beecham Biolog
Priority to CA002383413A priority patent/CA2383413A1/en
Priority to BR0014282-4A priority patent/BR0014282A/en
Priority to IL14867200A priority patent/IL148672A0/en
Publication of WO2001021207A2 publication Critical patent/WO2001021207A2/en
Publication of WO2001021207A3 publication Critical patent/WO2001021207A3/en
Priority to NO20021433A priority patent/NO20021433L/en
Priority to HK02109233.6A priority patent/HK1049106A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Abstract

The invention relates to a novel adjuvant system comprising a polyoxyethylene sorbitan ester surfactant in combination with an octoxynol and vaccines comprising the adjuvant system together with an antigen. Further provided are methods of manufacturing the adjuvants and vaccines and the use of the adjuvants and vaccines in the prophylaxis or therapy of disease.
PCT/EP2000/009366 1999-09-24 2000-09-22 Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines WO2001021207A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
BR0014282-4A BR0014282A (en) 1999-09-24 2000-09-22 Vaccines
IL14867200A IL148672A0 (en) 1999-09-24 2000-09-22 Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
CA002383413A CA2383413A1 (en) 1999-09-24 2000-09-22 Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
EP00969296A EP1221971A2 (en) 1999-09-24 2000-09-22 Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
MXPA02003067A MXPA02003067A (en) 1999-09-24 2000-09-22 Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines.
JP2001524631A JP2003509473A (en) 1999-09-24 2000-09-22 vaccine
AU79070/00A AU765824B2 (en) 1999-09-24 2000-09-22 Vaccines
KR1020027003832A KR20020038770A (en) 1999-09-24 2000-09-22 Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
HU0202885A HUP0202885A3 (en) 1999-09-24 2000-09-22 Vaccines
NO20021433A NO20021433L (en) 1999-09-24 2002-03-21 vaccinations
HK02109233.6A HK1049106A1 (en) 1999-09-24 2002-12-19 Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9922703.5A GB9922703D0 (en) 1999-09-24 1999-09-24 Vaccine
GB9922703.5 1999-09-24
GB0016685.0 2000-07-06
GB0016685A GB0016685D0 (en) 2000-07-06 2000-07-06 Novel compounds

Publications (2)

Publication Number Publication Date
WO2001021207A2 WO2001021207A2 (en) 2001-03-29
WO2001021207A3 true WO2001021207A3 (en) 2001-09-27

Family

ID=26244613

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/009366 WO2001021207A2 (en) 1999-09-24 2000-09-22 Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines

Country Status (17)

Country Link
EP (1) EP1221971A2 (en)
JP (1) JP2003509473A (en)
KR (1) KR20020038770A (en)
CN (1) CN1391483A (en)
AU (1) AU765824B2 (en)
BR (1) BR0014282A (en)
CA (1) CA2383413A1 (en)
CO (1) CO5200837A1 (en)
CZ (1) CZ20021043A3 (en)
HK (1) HK1049106A1 (en)
HU (1) HUP0202885A3 (en)
IL (1) IL148672A0 (en)
MX (1) MXPA02003067A (en)
NO (1) NO20021433L (en)
PL (1) PL355163A1 (en)
TR (1) TR200200774T2 (en)
WO (1) WO2001021207A2 (en)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0909323B1 (en) 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Helicobacter pylori bacterioferritin
CA2425303A1 (en) 2000-10-27 2002-05-02 John Telford Nucleic acids and proteins from streptococcus groups a & b
CA2430379A1 (en) 2000-12-07 2002-06-13 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
CA2489292A1 (en) 2002-06-13 2003-12-24 Chiron Corporation Vectors for expression of hml-2 polypeptides
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
DK2351579T3 (en) 2002-10-11 2017-01-09 Novartis Vaccines And Diagnostics S R L Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages.
EP2279746B1 (en) 2002-11-15 2013-10-02 Novartis Vaccines and Diagnostics S.r.l. Surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
EP2289546A3 (en) 2003-01-30 2011-03-30 Novartis Vaccines and Diagnostics S.r.l. Injectable vaccines against multiple meningococcal serogroups
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
ES2529736T3 (en) 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Immunogenic composition comprising a SARS coronavirus spicular protein
WO2005020964A1 (en) 2003-06-02 2005-03-10 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
EP1670506B1 (en) 2003-10-02 2012-11-21 Novartis AG Liquid vaccines for multiple meningococcal serogroups
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
BRPI0510315A (en) 2004-04-30 2007-10-16 Chiron Srl integration of meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
US20090104226A1 (en) 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
US20060165716A1 (en) 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
EP2433647A3 (en) 2005-01-27 2012-06-06 Children's Hospital & Research Center at Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
WO2006089264A2 (en) 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
JP2008530245A (en) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Antigens from uropathogenic strains
JP5006196B2 (en) 2005-08-01 2012-08-22 久光製薬株式会社 Adjuvants and formulations for transdermal or transmucosal administration
EP1945247A1 (en) 2005-10-18 2008-07-23 Novartis Vaccines and Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
HUE051122T2 (en) 2005-11-04 2021-03-01 Seqirus Uk Ltd Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP1945253A2 (en) * 2005-11-04 2008-07-23 Novartis Vaccines and Diagnostics S.r.l. Adminstration routes for priming/boosting with influenza vaccines
ES2514316T3 (en) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
PT2478916T (en) 2006-01-27 2020-07-03 Seqirus Uk Ltd Influenza vaccines containing hemagglutinin and matrix proteins
US8535683B2 (en) 2006-03-22 2013-09-17 Abbott Biologicals B.V. Intranasal or inhalational administration of virosomes
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2382987A1 (en) 2006-03-24 2011-11-02 Novartis Vaccines and Diagnostics GmbH Storage of influenza vaccines without refrigeration
CA2647942A1 (en) 2006-03-31 2007-11-08 Novartis Ag Combined mucosal and parenteral immunization against hiv
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
ES2536401T3 (en) 2006-09-11 2015-05-25 Novartis Ag Making vaccines against influenza viruses without using eggs
US20110045022A1 (en) 2006-12-06 2011-02-24 Theodore Tsai Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US20100047327A1 (en) * 2007-01-31 2010-02-25 Tetsuji Kuwahara Adjuvant for Transdermal or Transmucosal Administration and Pharmaceutical Preparation Containing the Same
PT2185191E (en) 2007-06-27 2012-11-27 Novartis Ag Low-additive influenza vaccines
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
JP2011506334A (en) 2007-12-07 2011-03-03 ノバルティス アーゲー Composition for inducing an immune response
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
NZ586430A (en) 2007-12-21 2012-09-28 Novartis Ag Mutant forms of streptolysin o (slo)
CA2716212A1 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
EP2265640B1 (en) 2008-03-10 2015-11-04 Children's Hospital & Research Center at Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
EP2376108B1 (en) 2008-12-09 2017-02-22 Pfizer Vaccines LLC IgE CH3 PEPTIDE VACCINE
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
MX2011007456A (en) 2009-01-12 2011-08-03 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria.
CA2751379C (en) 2009-02-10 2018-06-12 Novartis Ag Influenza vaccines with reduced amounts of squalene
AU2010220103A1 (en) 2009-03-06 2011-09-22 Novartis Ag Chlamydia antigens
SG175092A1 (en) 2009-04-14 2011-11-28 Novartis Ag Compositions for immunising against staphylococcus aerus
ES2552153T3 (en) 2009-04-30 2015-11-26 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
EP2442826B1 (en) 2009-06-15 2015-07-08 National University of Singapore Influenza vaccine, composition, and methods of use
ES2662716T3 (en) 2009-07-07 2018-04-09 Glaxosmithkline Biologicals Sa Preserved immunogens of Escherichia coli
SG178026A1 (en) 2009-07-15 2012-03-29 Novartis Ag Rsv f protein compositions and methods for making same
ES2526996T3 (en) 2009-07-16 2015-01-19 Novartis Ag Detoxified immunogens from Escherichia coli
PE20120817A1 (en) 2009-07-30 2012-07-07 Pfizer Vaccines Llc ANTIGENIC TAU PEPTIDES AND USES OF THEM
NZ598458A (en) 2009-08-27 2014-03-28 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
CA2846746A1 (en) 2009-09-03 2011-03-10 Pfizer Vaccines Llc Pcsk9 vaccine
US8974799B2 (en) 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
JP5960055B2 (en) 2009-10-27 2016-08-02 ノバルティス アーゲー Modified meningococcal fHBP polypeptide
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
KR20120120185A (en) 2009-12-22 2012-11-01 셀덱스 쎄라퓨틱스, 인크. Vaccine compositions
EP2519265B1 (en) 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA Polysaccharide immunogens conjugated to e. coli carrier proteins
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
EP2552942B1 (en) 2010-03-30 2017-12-27 Children's Hospital & Research Center at Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011130379A1 (en) 2010-04-13 2011-10-20 Novartis Ag Benzonapthyridine compositions and uses thereof
EP2576613A1 (en) 2010-06-07 2013-04-10 Pfizer Inc. Her-2 peptides and vaccines
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
EP3153578A1 (en) 2010-07-06 2017-04-12 Novartis Ag Norovirus derived immunogenic compositions and methods
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
AU2012211278B2 (en) 2011-01-26 2016-11-10 Glaxosmithkline Biologicals Sa RSV immunization regimen
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
LT2707385T (en) 2011-05-13 2017-12-11 Glaxosmithkline Biologicals Sa Pre-fusion rsv f antigens
EP3508219A1 (en) 2011-07-06 2019-07-10 GlaxoSmithKline Biologicals S.A. Self-replicating rna prime - protein boost vaccines
EP3332802A1 (en) 2011-07-06 2018-06-13 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
ES2687129T3 (en) 2011-07-25 2018-10-23 Glaxosmithkline Biologicals Sa Compositions and methods to evaluate the functional immunogenicity of parvovirus vaccines
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
PE20142406A1 (en) 2012-05-04 2015-01-23 Pfizer ANTIGENS ASSOCIATED WITH PROSTATE AND VACCINE-BASED IMMUNOTHERAPY REGIMES
CN104736180A (en) 2012-05-22 2015-06-24 诺华股份有限公司 Meningococcus serogroup X conjugate
CN104853770A (en) 2012-07-06 2015-08-19 诺华股份有限公司 Immunogenic compositions and uses thereof
MX2015004171A (en) 2012-10-02 2015-10-22 Glaxosmithkline Biolog Sa Nonlinear saccharide conjugates.
AU2013326503B2 (en) 2012-10-03 2018-04-19 Glaxosmithkline Biologicals Sa Immunogenic composition
ES2656510T3 (en) 2012-11-30 2018-02-27 Glaxosmithkline Biologicals S.A. Pseudomonas antigens and antigen combination
WO2015132619A1 (en) 2013-05-15 2015-09-11 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
JP6114401B2 (en) 2013-10-31 2017-04-12 久光製薬株式会社 Adjuvant composition, adjuvant preparation containing the same, and kit
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2015208821B2 (en) 2014-01-21 2017-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3104877B1 (en) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
JP6796057B2 (en) 2014-07-23 2020-12-02 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド H factor binding protein mutant and its usage
DK3244917T3 (en) 2015-01-15 2023-05-22 Pfizer Immunogenic compositions for use in pneumococcal vaccines
AU2016271857B2 (en) 2015-06-03 2020-05-28 Affiris Ag IL-23-P19 vaccines
CN107849119A (en) 2015-07-07 2018-03-27 阿费里斯股份公司 For the vaccine for the disease for treating and preventing IgE mediations
NZ739007A (en) 2015-07-21 2022-08-26 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3377098A1 (en) 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
BR112018013967A2 (en) 2016-01-19 2019-02-05 Pfizer cancer vaccines
ES2911490T3 (en) 2017-01-20 2022-05-19 Pfizer Immunogenic compositions for use in pneumococcal vaccines
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3893926A1 (en) 2018-12-12 2021-10-20 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP7239509B6 (en) 2019-02-22 2023-03-28 ファイザー・インク Method for purifying bacterial polysaccharides
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2021084429A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
IL295713A (en) 2020-02-21 2022-10-01 Pfizer Purification of saccharides
PE20230170A1 (en) 2020-02-23 2023-02-01 Pfizer ESCHERICHIA COLI COMPOSITIONS AND THEIR METHODS
PE20231934A1 (en) 2020-10-27 2023-12-01 Pfizer COMPOSITIONS OF ESCHERICHIA COLI AND METHODS THEREOF
JP2022075575A (en) 2020-11-04 2022-05-18 ファイザー・インク Immunogenic compositions for use in pneumococcal vaccines
CA3200968A1 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TWI750929B (en) * 2020-12-02 2021-12-21 林建宏 Temperature-sensitive adjuvant for aerosol immunity and its preparation method
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
JP2024507828A (en) 2021-02-19 2024-02-21 サノフィ パスツール インコーポレイテッド Group B meningococcal recombinant vaccine
WO2022234483A1 (en) 2021-05-04 2022-11-10 King Abdullah University Of Science And Technology Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
US20220387576A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112023023671A2 (en) 2021-05-28 2024-02-06 Pfizer IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACHARIDE ANTIGENS AND USES THEREOF
WO2023079529A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Re-focusing protein booster immunization compositions and methods of use thereof
WO2023079528A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
WO2023092090A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024018061A1 (en) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Use of bordetella strains for the treatment of chronic obstructive pulmonary disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0182401A1 (en) * 1984-10-19 1986-05-28 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Vaccines comprising immunogenic protein or peptide complexes
EP0242643A2 (en) * 1986-04-23 1987-10-28 Fisons Corporation Nasal administration of drugs
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
EP0182401A1 (en) * 1984-10-19 1986-05-28 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Vaccines comprising immunogenic protein or peptide complexes
EP0242643A2 (en) * 1986-04-23 1987-10-28 Fisons Corporation Nasal administration of drugs
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BELSHE R B ET AL: "THE EFFICACY OF LIVE ATTENUATED, COLD-ADAPTED, TRIVALENT, INTRANASAL INFLUENZAVIRUS VACCINE IN CHILDREN", NEW ENGLAND JOURNAL OF MEDICINE, THE,US,MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, vol. 338, no. 20, 1998, pages 1405 - 1412, XP000914636, ISSN: 0028-4793 *
GROSS P A ET AL: "COMPARISON OF NEW TRITON X-100 TREATED AND TWEEN ETHER TREATED SPLIT PRODUCT VACCINES IN CHILDREN", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 14, no. 5, 1981, pages 534 - 538, XP000990520, ISSN: 0095-1137 *

Also Published As

Publication number Publication date
CA2383413A1 (en) 2001-03-29
NO20021433D0 (en) 2002-03-21
KR20020038770A (en) 2002-05-23
CZ20021043A3 (en) 2002-08-14
AU7907000A (en) 2001-04-24
CN1391483A (en) 2003-01-15
EP1221971A2 (en) 2002-07-17
TR200200774T2 (en) 2002-08-21
HUP0202885A2 (en) 2002-12-28
PL355163A1 (en) 2004-04-05
IL148672A0 (en) 2002-09-12
MXPA02003067A (en) 2002-09-30
WO2001021207A2 (en) 2001-03-29
HK1049106A1 (en) 2003-05-02
HUP0202885A3 (en) 2004-07-28
BR0014282A (en) 2002-05-21
NO20021433L (en) 2002-05-21
JP2003509473A (en) 2003-03-11
AU765824B2 (en) 2003-10-02
CO5200837A1 (en) 2002-09-27

Similar Documents

Publication Publication Date Title
WO2001021207A3 (en) Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
AR025750A1 (en) VACCINES
WO2003028760A3 (en) Vaccine
WO2001034801A3 (en) Recombinant gelatin in vaccines
EP2246067A3 (en) Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
AU2003235707A1 (en) Immunogenic preparations and vaccines on the basis of mrna
WO2002013857A3 (en) A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
HUP0203817A2 (en) Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
WO2002009746A3 (en) Vaccines comprising outer membrane vesciles from gram negative bacteria
WO2000057917A3 (en) Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
EP2275122A3 (en) Protein-based streptococcus pneumoniae vaccines
WO2003066094A3 (en) Hepatitis b vaccines
WO2000062801A3 (en) Combination vaccine against streptococcus pneumoniae and respiratory syncytial virus (rsv)
WO2003059385A3 (en) Hiv vaccine and method of use
AU2002324073A1 (en) Vaccine therapies and prophylactic treatments of atherosclerotic diseases
WO2003080111A3 (en) Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
WO2002009752A3 (en) Immunological adjuvant compounds
WO2001070265A3 (en) Lipopeptide adjuvants
NO20024255D0 (en) HIV Immune Adjuvant Therapy
WO2000006198A3 (en) Adjuvant comprising pulmonary surfactant
WO2002076384A3 (en) Therapeutic compositions that alter the immune response
AU2002312487A1 (en) Nucleoside vaccine adjuvants
AU2002342949A1 (en) Vaccine composition comprising at least two valences, one with enhanced adjuvant and not the other
HUP0401182A3 (en) Vaccine composition comprising at least two valences, one enhanced with adjuvant and not the other
AU2002320079A1 (en) Vaccines, immunotherapeutics and methods of using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 148672

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 79070/00

Country of ref document: AU

Ref document number: IN/PCT/2002/413/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002/02270

Country of ref document: ZA

Ref document number: 517902

Country of ref document: NZ

Ref document number: 200202270

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2383413

Country of ref document: CA

Ref document number: PA/a/2002/003067

Country of ref document: MX

Ref document number: PV2002-1043

Country of ref document: CZ

Ref document number: 2002/00774

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1020027003832

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2001 524631

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000969296

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 008160147

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020027003832

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000969296

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10110286

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV2002-1043

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: PV2002-1043

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 79070/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000969296

Country of ref document: EP